Letrozole: Present and future role in the treatment of breast cancer

Surabhi Amar, Vivek Roy, Edith A. Perez

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


State of the art hormonal therapy for women with breast cancer has evolved over the last few years. Tamoxifen used to be the gold standard for adjuvant treatment of postmenopausal women with hormone-sensitive early breast cancer and also for patients with metastatic disease in whom hormonal manipulation was considered, but the introduction of third generation aromatase inhibitors has changed this concept. This article discusses the clinical implications of recent trials with one of the aromatase inhibitors letrozole, including pharmacokinetic and pharmacodynamic data as well as recent data on relative benefits and side effects compared with other available hormonal agents. Relevant ongoing clinical-translational trials evaluating this agent are also discussed.

Original languageEnglish (US)
Pages (from-to)1965-1975
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Issue number12
StatePublished - Aug 2007


  • Ajuvant therapy
  • Anti-estrogens
  • Aromatase inhibitor
  • Breast cancer
  • Letrozole

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Letrozole: Present and future role in the treatment of breast cancer'. Together they form a unique fingerprint.

Cite this